Literature DB >> 15578008

Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients.

A John Rush1, Madhukar H Trivedi, Thomas J Carmody, Hisham M Ibrahim, John C Markowitz, Gabor I Keitner, Susan G Kornstein, Bruce Arnow, Daniel N Klein, Rachel Manber, David L Dunner, Alan J Gelenberg, James H Kocsis, Charles B Nemeroff, Jan Fawcett, Michael E Thase, James M Russell, Darlene N Jody, Frances E Borian, Martin B Keller.   

Abstract

This study evaluated and compared the performance of three self-report measures: (1) 30-item Inventory of Depressive Symptomatology-Self-Report (IDS-SR30); (2) 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16); and (3) Patient Global Impression-Improvement (PGI-I) in assessing clinical outcomes in depressed patients during a 12-week, acute phase, randomized, controlled trial comparing nefazodone, cognitive-behavioral analysis system of psychotherapy (CBASP), and the combination in the treatment of chronic depression. The IDS-SR30, QIDS-SR16, PGI-I, and the 24-item Hamilton Depression Rating Scale (HDRS24) ratings were collected at baseline and at weeks 1-4, 6, 8, 10, and 12. Response was defined a priori as a > or =50% reduction in baseline total score for the IDS-SR30 or for the QIDS-SR16 or as a PGI-I score of 1 or 2 at exit. Overall response rates (LOCF) to nefazodone were 41% (IDS-SR30), 45% (QIDS-SR16), 53% (PCI-I), and 47% (HDRS17). For CBASP, response rates were 41% (IDS-SR30), 45% (QIDS-SR16), 48% (PGI-I), and 46% (HDRS17). For the combination, response rates were 68% (IDS-SR30 and QIDS-SR16), 73% (PGI-I), and 76% (HDRS17). Similarly, remission rates were comparable for nefazodone (IDS-SR30=32%, QIDS-SR16=28%, PGI-I=22%, HDRS17=30%), for CBASP (IDS-SR30=32%, QIDS-SR16=30%, PGI-I=21%, HDRS17=32%), and for the combination (IDS-SR30=52%, QIDS-SR16=50%, PGI-I=25%, HDRS17=49%). Both the IDS-SR30 and QIDS-SR16 closely mirrored and confirmed findings based on the HDRS24. These findings raise the possibility that these two self-reports could provide cost- and time-efficient substitutes for clinician ratings in treatment trials of outpatients with nonpsychotic MDD without cognitive impairment. Global patient ratings such as the PGI-I, as opposed to specific item-based ratings, provide less valid findings.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15578008     DOI: 10.1038/sj.npp.1300614

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  36 in total

1.  Psychometric properties of the Quick Inventory of Depressive Symptomatology in adolescents.

Authors:  Ira H Bernstein; A John Rush; Madhukar H Trivedi; Carroll W Hughes; Laurie Macleod; Bradley P Witte; Shailesh Jain; Taryn L Mayes; Graham J Emslie
Journal:  Int J Methods Psychiatr Res       Date:  2010-12       Impact factor: 4.035

2.  Genome-wide association study of antidepressant treatment-emergent suicidal ideation.

Authors:  Andreas Menke; Katharina Domschke; Darina Czamara; Torsten Klengel; Johannes Hennings; Susanne Lucae; Bernhard T Baune; Volker Arolt; Bertram Müller-Myhsok; Florian Holsboer; Elisabeth B Binder
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

3.  Problem-solving education to prevent depression among low-income mothers of preterm infants: a randomized controlled pilot trial.

Authors:  Michael Silverstein; Emily Feinberg; Howard Cabral; Sara Sauder; Lucia Egbert; Elisabeth Schainker; Karen Kamholz; Mark Hegel; William Beardslee
Journal:  Arch Womens Ment Health       Date:  2011-06-12       Impact factor: 3.633

Review 4.  Assessing physicians' use of treatment algorithms: Project IMPACTS study design and rationale.

Authors:  Madhukar H Trivedi; Cynthia A Claassen; Bruce D Grannemann; T Michael Kashner; Thomas J Carmody; Ella Daly; Janet K Kern
Journal:  Contemp Clin Trials       Date:  2006-08-16       Impact factor: 2.226

5.  An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report.

Authors:  A John Rush; Ira H Bernstein; Madhukar H Trivedi; Thomas J Carmody; Stephen Wisniewski; James C Mundt; Kathy Shores-Wilson; Melanie M Biggs; Ada Woo; Andrew A Nierenberg; Maurizio Fava
Journal:  Biol Psychiatry       Date:  2005-09-30       Impact factor: 13.382

6.  Psychometric properties of an automated telephone-based PHQ-9.

Authors:  Ramesh Farzanfar; Timothy Hereen; Joseph Fava; Jillian Davis; Louis Vachon; Robert Friedman
Journal:  Telemed J E Health       Date:  2013-11-12       Impact factor: 3.536

7.  Effects of Restricted Time in Bed on Antidepressant Treatment Response: A Randomized Controlled Trial.

Authors:  J Todd Arnedt; Leslie M Swanson; Richard R Dopp; Holli S Bertram; Ann J Mooney; Edward D Huntley; Robert F Hoffmann; Roseanne Armitage
Journal:  J Clin Psychiatry       Date:  2016-10       Impact factor: 4.384

8.  Results from a trial of an unsupported internet intervention for depressive symptoms.

Authors:  Yan Leykin; Ricardo F Muñoz; Omar Contreras; Melissa D Latham
Journal:  Internet Interv       Date:  2014-10-01

9.  Interaction of oxytocin level and past depression may predict postpartum depressive symptom severity.

Authors:  Suena H Massey; Stephanie A Schuette; Hossein Pournajafi-Nazarloo; Katherine L Wisner; C Sue Carter
Journal:  Arch Womens Ment Health       Date:  2016-03-08       Impact factor: 3.633

10.  Validation of depression screening scales in patients with CKD.

Authors:  S Susan Hedayati; Abu T Minhajuddin; Robert D Toto; David W Morris; A John Rush
Journal:  Am J Kidney Dis       Date:  2009-06-03       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.